Trials / Not Yet Recruiting
Not Yet RecruitingNCT06817096
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
Phase 3, Multicenter, Parallel, Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Nitazoxanide 600 Mg Administered Twice Daily, in the Outpatient Treatment of COVID-19 and Influenza
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 340 (estimated)
- Sponsor
- Azidus Brasil · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
2\. Participants will: * Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. * Visit the clinic on the 7th day of treatment for a check-up and safety tests. * Keep a diary of their symptoms and other medications used
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitazoxanide 600Mg Oral Tablet / placebo oral tablet | 1 tablet every 12 hours |
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2025-02-10
- Last updated
- 2025-02-10
Source: ClinicalTrials.gov record NCT06817096. Inclusion in this directory is not an endorsement.